Get the Stockscreener App
755.39
0.12%
-0.89
After Hours:
753.50
-1.89
-0.25%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $755.39, with a volume of 2.20M.
It is down -0.12% in the last 24 hours and up +18.13% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$756.28
Open:
$760.17
24h Volume:
2.20M
Relative Volume:
0.51
Market Cap:
$714.94B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
49.37
EPS:
15.3
Net Cash Flow:
$-50.20M
1W Performance:
+3.88%
1M Performance:
+18.13%
6M Performance:
-8.09%
1Y Performance:
-19.21%
1-Day Range:
$748.00
$761.60
1-Week Range:
$719.22
$761.60
52-Week Range:
$623.78
$942.35
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
755.39 | 676.48B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.06 | 423.36B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.34 | 373.87B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
124.12 | 244.98B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
82.81 | 209.89B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Astra, Lilly are latest to reevaluate U.K. investments after Merck’s pullback: reports - MSN
Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case - Benzinga
Eli Lilly (LLY) Gains Edge in Obesity Market - GuruFocus
Lilly launches AI-enabled drug discovery platform - Health Tech World
Takeda taps longtime Lilly exec as US head—Chutes & Ladders - Fierce Biotech
This Under-the-Radar Healthcare Stock Could Soar in 2026 - The Motley Fool
Ousted FDA official joins Lilly; Novo names global research head as layoffs come into focus - Endpoints News
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street - AOL.com
Medical company Eli Lilly plans to build $5.9 billion manufacturing campus in Houston - Click2Houston
7th Circ. Backs $183M FCA Award Over Eli Lilly Drug Rebates - Law360
Eli Lilly launches TuneLab to share AI drug discovery models with biotechs - drugdiscoverytrends.com
Takeda recruits Lilly executive to run US operations out of Cambridge - The Boston Globe
Eli Lilly loses appeal of $183.7 million Medicaid fraud award - MSN
Eli Lilly (LLY) Ordered to Pay $183.7M for Medicaid Fraud - GuruFocus
FILE PHOTO: Eli Lilly logo is shown on one of their offices in San Diego - Colorado Springs Gazette
Eli Lilly’s Phase 1 Study of LY3985297: Key Insights for Investors - TipRanks
Eli Lilly Loses Appeal of $193 Million Award in Fraud Suit (1) - Bloomberg Law News
Chelsea Counsel Co. Sells 925 Shares of Eli Lilly and Company $LLY - MarketBeat
Leading Pharma Giant Eli Lilly's CFO to Share Strategic Insights at Bernstein Healthcare Forum - Stock Titan
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally - AOL.com
Eli Lilly & Co: Hold Rating Amid Promising Jaypirca Results and Market Caution - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Sept 2025) - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Trading Up 1.3%Here's What Happened - MarketBeat
Lilly rival Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs - Indianapolis Business Journal
Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly - AOL.com
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,190 - 富途牛牛
Novo Tries To Catch Up With Lilly By Slashing 11% Of Workforce - NDTV Profit
Eli Lilly (LLY) CEO Buys $1 Million of Company Stock After Recent Crash - MSN
Novo Tries to Catch Up With Lilly by Slashing 11% of Workforce - Bloomberg.com
Eli Lilly launches AI-powered drug development platform for biotech operators - Mugglehead Magazine
Eli Lilly & Co’s Strong Growth Potential and Strategic Positioning in the Obesity Drug Market Reinforces Buy Rating - TipRanks
Eli Lilly & Co’s Tirzepatide: Promising Outlook and Buy Rating Backed by ICER’s Positive Evaluation - TipRanks
Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies - MSN
Here's why Eli Lilly (LLY) is up today - Investorsobserver
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary' - Benzinga
Lilly to give biotech startups access to AI tools - BioPharma Dive
Defiance Has A New ETF For High-Stakes Pharma Traders - Benzinga
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’ - Stocktwits
Eli Lilly (LLY) Announces New AI Platform to Accelerate Drug Discoveries - TipRanks
Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data - Benzinga
Lilly launches AI-powered platform to accelerate drug discovery - Reuters
Eli Lilly launches AI platform for drug discovery - Proactive financial news
Lilly looks into gene therapies for obesity - statnews.com
Lilly launches AI platform TuneLab for biotech firms (LLY:NYSE) - Seeking Alpha
Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health - Eli Lilly and Company
Eli Lilly and Co launches the TuneLab platform, opening AI drug discovery models to biotechnology companies. - 富途牛牛
Eli Lilly (LLY) Launches AI-Powered Drug Discovery Platform - GuruFocus
Lilly launches AI platform for biotechs with $1 billion worth of data - Investing.com
Eli Lilly Launches $1 Bln AI Drug Discovery Platform TuneLab - Nasdaq
Eli Lilly launches platform for AI-enabled drug discovery - Reuters
Lilly will let small biotechs use its AI models at no cost - statnews.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):